Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
about
Multigene testing of moderate-risk genes: be mindful of the missensePioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical ScienceSurvival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.Low prevalence of CHEK2 gene mutations in multiethnic cohorts of breast cancer patients in Malaysia.Growing recognition of the role for rare missense substitutions in breast cancer susceptibilityPrevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast CancersSensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriersPatient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association ConsortiumBRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation?Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing.Hereditary breast cancer: the era of new susceptibility genes.Dissecting the genotype in syndromic intellectual disability using whole exome sequencing in addition to genome-wide copy number analysis.Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation.Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population.Pancreatic cancer as a sentinel for hereditary cancer predisposition.
P2860
Q24658557-A77E5267-C521-4659-B718-D37FAEFE2694Q28654820-97900205-A7A0-4EFF-A638-912A6245CDDEQ34113473-992060D2-8F5B-48FE-82AB-5021155776A1Q34560743-F79440D2-9EBA-4913-8261-C4DEF0B9FAEFQ35023623-D4250927-5A3D-460B-BF3F-45F191DA433CQ35106767-9D10958C-2EDC-4B59-B5E8-DD9AC483C5C4Q35665705-31A3993E-2C1E-42F0-AA1C-A05D37F909A7Q35977371-EA8EFF9F-17E1-446A-B7DA-F281115DB303Q37307937-205B4BBA-07E9-4B5E-B710-770C71221167Q37665135-AEF49872-6E64-4DF6-8078-7920157CEA6FQ38136335-776A9154-E42C-4128-BD5D-3A2916DF9019Q39398050-A9CECC28-BBC4-446D-B7F7-CB12E5F429B2Q39657506-9B981298-B30B-460C-81A9-8141B80C6FF4Q43651528-E76B854E-9481-44C3-8049-4D70CBEF9C74Q49097031-37D2FD9D-1B52-4E04-89DB-8AE2F7B59A3FQ51156403-389233F6-84E8-48B1-B969-5B4E049DADEEQ52586097-87D7005E-6E9D-49B6-8AEE-DC728D5BCBA2Q55280273-10145C39-F27C-4A24-B5F9-032091503324Q55443512-4A312A21-2C2B-47BB-9737-36858B5799B8
P2860
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
@ast
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
@en
type
label
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
@ast
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
@en
prefLabel
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
@ast
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
@en
P2860
P356
P1476
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
@en
P2093
Jake Higgins
Wendy Roeb
P2860
P304
P356
10.1093/HMG/DDS101
P577
2012-03-13T00:00:00Z